These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19915976)

  • 1. Fifteen-year trends in metastatic breast cancer survival in Greece.
    Dafni U; Grimani I; Xyrafas A; Eleftheraki AG; Fountzilas G
    Breast Cancer Res Treat; 2010 Feb; 119(3):621-31. PubMed ID: 19915976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
    Gennari A; Conte P; Rosso R; Orlandini C; Bruzzi P
    Cancer; 2005 Oct; 104(8):1742-50. PubMed ID: 16149088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
    Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy for breast cancer.
    Hennessy BT; Pusztai L
    Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current trends in pharmacotherapy of breast cancer].
    Boér K
    Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
    Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
    Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy of metastatic breast cancer: the truth beyond the clinical trials.
    Gueth U; Huang DJ; Schoetzau A; Holzgreve W; Wight E
    Oncology; 2009; 76(4):247-53. PubMed ID: 19246949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors.
    Brun B; Benchalal M; Lebas C; Piedbois P; Lin M; Lebourgeois JP
    Cancer; 1997 Jun; 79(11):2137-46. PubMed ID: 9179060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
    Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
    J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Does primary tumor affect the prognosis in postmastectomy locoregional recurrence in breast carcinoma?].
    Willner J; Kiricuta IC; Kölbl O
    Strahlenther Onkol; 1995 Jan; 171(1):18-28. PubMed ID: 7839301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
    Roché H; Yelle L; Cognetti F; Mauriac L; Bunnell C; Sparano J; Kerbrat P; Delord JP; Vahdat L; Peck R; Lebwohl D; Ezzeddine R; Curé H
    J Clin Oncol; 2007 Aug; 25(23):3415-20. PubMed ID: 17606972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
    Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.